Atlas Trials

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT01292135 · COMPLETED

Trial details

NCT number
NCT01292135
Sponsor
Pharmacyclics LLC.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Start date
2011-02-01
Primary completion
2012-11-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.